Arthneeti
All Q2 FY27 results →
TC

Tatva Chintan

Q2 FY27Chemicals & Petrochemicals

Tatva Chintan Q2 FY27 investor presentation: Revenue & Margins

Q2 FY27 investor presentation: what the company reported on revenue, margins and projects.

Price₹1,944
Market cap₹4.5K Cr
P/E86.8
Updated19 Oct 2026
Read3 min read

Based on Tatva Chintan's Q2 FY27 investor presentation. The company has not published an earnings-call transcript for this quarter, so figures here are what the investor presentation reports, not management guidance.

The short version

Q2 FY27 revenue from operations: ₹2,173 Mn, up 76% YoY from ₹1,235 Mn in Q2 FY26 (Page 11). Q2FY27 EBITDA (Excl.

From Tatva Chintan's Q2 FY27 earnings-call transcript · updated 19 Oct 2026.

Revenue & Sales Performance

  • Q2 FY27 revenue from operations: ₹2,173 Mn, up 76% YoY from ₹1,235 Mn in Q2 FY26 (Page 11).
  • Total income in Q2 FY27: ₹2,191 Mn, up 76% YoY (Page 11).
  • H1 FY27 revenue from operations: ₹3,844 Mn, up 60% YoY from ₹2,404 Mn in H1 FY26 (Pages 9, 11).
  • Q2 FY27 EBITDA (excl. other income): ₹407 Mn, up 83% YoY; EBITDA margin 19% (Page 11).
  • Q2 FY27 PAT: ₹215 Mn, up 116% YoY; PAT margin 9.9% (Page 11).
  • No specific volume figures reported.

2 more points from Tatva Chintan's call on revenue

Pro opens every point from 15K+ earnings calls

Profitability & Margins

See what Tatva Chintan said on profitability & margins — free account, 30 seconds.

Capital Expenditure Plans

  • A new greenfield project is underway, progressing according to the planned schedule (Page 7).
  • This new facility will support growth by adding manufacturing capacity for organic expansion and commercialization of new molecules (Page 7).
  • Capital work-in-progress amounts in the balance sheet show significant investments: ₹2,307.44 Mn (31-Mar-23), ₹729.27 Mn (31-Mar-24), ₹215.35 Mn (31-Mar-25), ₹233.48 Mn (31-Mar-26), and ₹428.27 Mn (30-Sep-26) (Page 14).

2 more points from Tatva Chintan's call on capex

Pro opens every point from 15K+ earnings calls

Top-ranked in Chemicals & Petrochemicals

Ranked on what management guided this quarter

Guidance-ranked
1Shiv Texchem
Rev 1Mar 2
2Yasho Industries Ltd
Rev 1Mar 3
3
Rev 1Mar 3
4
Rev 1Mar 3
5
Rev 2Mar 1
Sign up free to see 3 moreTakes 30 seconds · no cardSign up

Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.

Fundraising & Capital Structure

See what Tatva Chintan said on fundraising & capital structure — free account, 30 seconds.

Order Book & Pipeline

The investor presentation for Tatva Chintan Pharma Chem Limited does not explicitly report specific data on order book, order inflow, or pending orders. The presentation primarily covers: - Financial performance including revenue, profit, and margins. - Operational highlights and product/category revenue splits. - Business outlook, including growth in specialty chemicals and new projects.

2 more points from Tatva Chintan's call on order book

Pro opens every point from 15K+ earnings calls

Tatva Chintan — Quarterly revenue & net profit

Revenue Net profit
Jun 2025Q1 FY26
Sep 2025Q2 FY26
Dec 2025Q3 FY26
Mar 2026Q4 FY26
Jun 2026Q1 FY27
Sep 2026Q2 FY27

Reported quarterly figures (₹ Cr). Latest (Q2 FY27): revenue ₹217 Cr, net profit ₹21 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.

Full financials →

Continue your research

What Tatva Chintan's management said in earlier quarters

Others in Chemicals & Petrochemicals this season

  • GOCL Corpn. (Q2 FY27)

    Year-on-year (YoY) increase in revenue from operations: Approximately 85% increase (41,063 vs. Key results statement takeaways from GOCL Corpn.'s Q2 FY27 result

  • AksharChem (I) (Q2 FY27)

    Year-on-year revenue growth for the quarter is approximately 79.7% [(16,048.24 . Key results statement takeaways from AksharChem (I)'s Q2 FY27 results statement

  • Bhansali Engineering Polymers Ltd (Q2 FY27)

    Revenue from operations (net) for the quarter ended 30/09/2026 is ₹40,336.95 lakhs, compared to ₹32,509.76 lakhs for the quarter ended 30/09/2025, reflecting a…

  • Rossari Biotech (Q2 FY27)

    4,195.12 million, an increase of approximately 18%. Key investor presentation takeaways from Rossari Biotech's Q2 FY27 investor presentation — and how it ranks

Compare:vs Solar Industriesvs Pidilite Inds.vs SRF Ltd

🔎 Who's planning the most growth?

Companies ranked by management's own guidance — revenue, margins, capex and order book, from every earnings call in India.

See rankings →

Arthneeti Pro · Annual

Tatva Chintan and 15K+ more earnings calls,
for less than your morning chai

a day

Every earnings call, ranking and concall Q&A across all four results seasons.

Secure Razorpay payment · instant access

Frequently Asked Questions

What were Tatva Chintan Q2 FY27 results?

Q2 FY27 revenue from operations: ₹2,173 Mn, up 76% YoY from ₹1,235 Mn in Q2 FY26 (Page 11). Q2FY27 EBITDA (Excl.

What is Tatva Chintan share price analysis?

Tatva Chintan currently shows a neutral. The stock trades at a P/E of 86.8 with a market cap of ₹4,547 Cr. Investors should review the full earnings analysis for detailed insights.

Is Tatva Chintan planning capital expenditure?

A new greenfield project is underway, progressing according to the planned schedule (Page 7).

Keep Tatva Chintan on your radar — track it to get its next earnings analysis in your feed.

This analysis is AI-generated based on publicly available earnings data and the company's investor presentation. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.